#MaxHealth is getting ready to heal the pain #SuperChartz
Key Levels:
Support: 830 Closing Basis
Resistance: 900, 999, 1099
Key Drivers:
Max Healthcare Institute Limited, India's second-largest hospital chain, offers a diverse array of healthcare services, including complex procedures like transplants, robotic surgeries, cardiac, neuro, orthopedic, and oncology surgeries. They have 17 facilities with a current capacity of ~3,530 beds, boasting a ~75% occupancy rate. Their Max Lab has 435+ partner-run CCs, 23 CoCCs, and ~170 PAS. Maxhome conducts 3,000+ daily billed transactions and has 14 specialized services. Max MyHealth, their digital platform, accounted for ~21% of H1FY24 revenues. They have significant strategic partnerships with Deakin University and Imperial College London, with ~1,000 high-index journal research publications in the last 5 years and 500 completed clinical research projects. Max recently acquired 550 bedded Sahara Hospital for ~Rs. 940 crs and aims to double its bed capacity with a planned brownfield expansion of ~2600 beds and potential to add 1,000 beds through land parcels. They plan to add beds in NCR as follows: FY24: 300 beds for Rs. 918 crs, FY25: 819 beds for Rs. 1592 crs, FY26: 1100 beds for Rs. 1377 crs, FY27: 521 beds for Rs. 552 crs, FY28: 1350 beds.
The company has a significant market capitalization of ₹84,041 Cr, with its current stock price at ₹865, fluctuating between a high of ₹910 and a low of ₹412. Its price-to-earnings ratio (P/E) stands high at 79.5, indicating investor optimism. The book value per share is ₹80.7, and the dividend yield is 0.12%. It maintains healthy returns with ROCE at 15.0% and ROE at 16.1%. The operating profit margin (OPM) is robust at 27.9%. The company's EPS is ₹10.9, and it demonstrates strong performance compared to the industry with a return over three months at 39.4% and return over three years at 65.2%. The return on assets is 11.4%, showcasing efficient asset utilization. It generated significant sales of ₹5,198 Cr. The enterprise value is ₹82,910 Cr, with an EVEBITDA ratio of 51.0. The debt-to-equity ratio is low at 0.08, reflecting a healthy financial structure. Overall, the company exhibits strong financials, profitability, and market performance.
Support: 830 Closing Basis
Resistance: 900, 999, 1099
Key Drivers:
Max Healthcare Institute Limited, India's second-largest hospital chain, offers a diverse array of healthcare services, including complex procedures like transplants, robotic surgeries, cardiac, neuro, orthopedic, and oncology surgeries. They have 17 facilities with a current capacity of ~3,530 beds, boasting a ~75% occupancy rate. Their Max Lab has 435+ partner-run CCs, 23 CoCCs, and ~170 PAS. Maxhome conducts 3,000+ daily billed transactions and has 14 specialized services. Max MyHealth, their digital platform, accounted for ~21% of H1FY24 revenues. They have significant strategic partnerships with Deakin University and Imperial College London, with ~1,000 high-index journal research publications in the last 5 years and 500 completed clinical research projects. Max recently acquired 550 bedded Sahara Hospital for ~Rs. 940 crs and aims to double its bed capacity with a planned brownfield expansion of ~2600 beds and potential to add 1,000 beds through land parcels. They plan to add beds in NCR as follows: FY24: 300 beds for Rs. 918 crs, FY25: 819 beds for Rs. 1592 crs, FY26: 1100 beds for Rs. 1377 crs, FY27: 521 beds for Rs. 552 crs, FY28: 1350 beds.
The company has a significant market capitalization of ₹84,041 Cr, with its current stock price at ₹865, fluctuating between a high of ₹910 and a low of ₹412. Its price-to-earnings ratio (P/E) stands high at 79.5, indicating investor optimism. The book value per share is ₹80.7, and the dividend yield is 0.12%. It maintains healthy returns with ROCE at 15.0% and ROE at 16.1%. The operating profit margin (OPM) is robust at 27.9%. The company's EPS is ₹10.9, and it demonstrates strong performance compared to the industry with a return over three months at 39.4% and return over three years at 65.2%. The return on assets is 11.4%, showcasing efficient asset utilization. It generated significant sales of ₹5,198 Cr. The enterprise value is ₹82,910 Cr, with an EVEBITDA ratio of 51.0. The debt-to-equity ratio is low at 0.08, reflecting a healthy financial structure. Overall, the company exhibits strong financials, profitability, and market performance.
Regards
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
SuperChartz
telegram.me/SuperChartz
Instagram.com/SuperChartz
facebook.com/SuperChartz
twitter.com/SuperChartz
youtube.com/@SuperChart
Get TradingView Premium 👇
in.tradingview.com/?aff_id=130166
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.